Sign inJoin waitlistJoin the waitlist

Thomas Eldridge Stinchcombe

Professor of Medicine · Duke Department of Medicine

Credentials: ·

History

Duke Department of Medicine
Present

University of North Carolina, Chapel Hill, School of Medicine
1998–2001
University of Michigan, Ann Arbor
1995–1998
University of Virginia, School of Medicine
1995

Research

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2,…
The Lancet Oncology · 2015 · 1,216 citations
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2023 · 1,050 citations
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
Journal of Clinical Oncology · 2002 · 595 citations

MS
Mark Socinski
53 papers
Everett Vokes
33 papers
Suresh Ramalingam
20 papers
Jeff Bradley
18 papers
Carrie Lee
14 papers
David Kozono
14 papers
Jeffrey Crawford
13 papers
KK
Karen Kelly
13 papers
Lin Gu
13 papers · 8 as a resident
JB
Jeffrey Bogart
12 papers
Nasser Altorki
12 papers
Ramaswamy Govindan
12 papers

Grants

Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $989.6K · Duke University
1997–2029
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $129.1K · Univ of North Carolina Chapel Hill
2005–2008

Clinical trials

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Principal investigator · Terminated · Phase 2
Duke University
2020–2023
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Principal investigator · Completed · Phase 2
Duke University
2018–2022
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Principal investigator · Terminated · Phase 2
Criterium, Inc.
2017–2021
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
Principal investigator · Completed · Phase 2
Academic and Community Cancer Research United
2012–2020